Predicting Response to BET Inhibitors Using a Computational Model and it's Validation: A Beat AML Project Study

Background: Despite advances in our understanding of the molecular pathogenesis of acute myeloid leukemia (AML), the prognosis remains poor, mainly due to high relapse rates. Therefore, novel treatment strategies are needed to improve therapeutic outcomes for AML patients.